Triple-negative Breast Cancer: Clinical Insights
Chapter 4In this video, Melinda L. Telli, MD, a medical oncologist at Stanford University in Palo Alto, California, discusses the treatment of patients with triple-negative breast cancer. While there are no fully U.S. Food and Drug Administration (FDA)-approved targeted therapies in this disease setting, there is a great deal of emerging research in this area.
2016 SABCS: Clinical Insights for Breast Cancer Treatment
In this video, Melinda L. Telli, MD, a medical oncologist at Stanford University in Palo Alto, California, discusses the research most likely to have a clinical impact presented at the 2016 San Antonio Breast Cancer Symposium (SABCS). Highlights include ways to reduce the risk of relapse among patients with ER-positive, HER2-negative early breast cancers.
Frontline Treatments for Patients With Metastatic Breast Cancer
In this video, Melinda L. Telli, MD, a medical oncologist at Stanford University in Palo Alto, California, discusses the frontline treatment of patients with metastatic breast cancer. One important phase 3 trial presented at 2016 SABCS tested the efficacy of fulvestrant against that anastrozole among patients with advanced ER-positive, HER2-negative metastatic breast cancer, though other treatment options are emerging.
ER-positive, HER2-negative Breast Cancer: A Changing Landscape
In this video, Melinda L. Telli, MD, a medical oncologist at Stanford University in Palo Alto, California, discusses how treatment is changing for patients with ER-positive, HER2-negative disease. Dr Telli notes different factors to consider before choosing a treatment combination for a specific patient, especially for patients whose disease is deemed to be high-risk.
